Treatment and outcomes of patients with HR+/HER2− early breast cancer in a real-world setting in Germany

Background: A subset of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer (HR+/HER2− EBC) are at higher risk of disease recurrence. Materials and Methods: This study utilised real-world data from the German Tumour Registry Breast Cancer (T...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Klaus-Ulrich Däßler, Volker Petersen, Mark-Oliver Zahn, Walid Fakhouri, Agnieszka Korfel, Anna Emde, Tatjana Rößler, Lisa Kruggel, Susanne Tech, Martina Jänicke, Katja Gratzke
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Elsevier 2026-01-01
Цуврал:	Cancer Treatment and Research Communications
Нөхцлүүд:	HR+/HER2− EBC High risk Non-high-risk
Онлайн хандалт:	http://www.sciencedirect.com/science/article/pii/S246829422600033X
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!